Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05217927 · ClinicalTrials.gov registry record · Phase 4
Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens
A Phase 4 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,415
- Enrollment target
NCT05217927 is a Phase 4 study that has completed, run by Pfizer. The registered enrollment target is 1,415 participants.
The verdict
NCT05217927, a Phase 4 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,415 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the efficacy and safety of daily and every other day dosing of rimegepant to placebo as a preventive treatment for episodic migraine.
Interventions
- DRUG Rimegepant 75mg daily dosing
- DRUG Rimegepant 75mg every other day dosing
- DRUG Placebo comparator dosing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,415 participants |
| Start Date | 2022-03-04 |
| Est. Completion | 2024-12-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05217927
The ClinicalTrials.gov registry entry for NCT05217927 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 1,415 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Rimegepant 75mg daily dosing is the first listed.
NCT05217927 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05217927 about?
NCT05217927 is a clinical study titled "Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens". The purpose of this study is to compare the efficacy and safety of daily and every other day dosing of rimegepant to placebo as a preventive treatment for episodic migraine.
What is the current status of trial NCT05217927?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,415 participants. The study started on 2022-03-04. Estimated completion is 2024-12-11.
What interventions are being tested in trial NCT05217927?
The interventions under investigation include: Rimegepant 75mg daily dosing (DRUG), Rimegepant 75mg every other day dosing (DRUG), Placebo comparator dosing (DRUG).
Who is sponsoring clinical trial NCT05217927?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.